• FirefoxInstall the new Firefox »
  •  Dow Up0.69% Nasdaq Up0.74%

    Vertex Pharmaceuticals Incorporated (VRTX)

    119.68 Up 0.25(0.21%) 11:35AM EST - Nasdaq Real Time Price
    Add to Portfolio
    ProfileGet Profile for:
    Vertex Pharmaceuticals Incorporated
    50 Northern Avenue
    Boston, MA 02210
    United States - Map
    Phone: 617-341-6100
    Website: http://www.vrtx.com

    Index Membership:N/A
    Full Time Employees:1,830

    Business Summary 

    Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases in specialty markets. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF); and advancing its research and early-stage development programs. It markets KALYDECO (ivacaftor) to treat patients of six years of age and older with CF who have the mutations in their cystic fibrosis transmembrane conductance regulator (CFTR) gene in the United States, Australia, Canada, and the European Union. The company also provides INCIVEK for the treatment of adults with genotype 1 hepatitis C virus infection. In addition, it is developing CFTR correctors, including lumacaftor in combination with ivacaftor, which has completed Phase III development program; and VX-661 in combination with ivacaftor, which is in Phase III development program. Further, it identifies and develops next-generation CFTR corrector compounds; and is involved in the research and early-stage development programs, including programs in the areas of oncology and neurology. Vertex Pharmaceuticals Incorporated sells its products principally to specialty pharmacy providers and wholesalers in North America, as well as government-owned and supported customers in international markets. The company has collaboration agreements with Cystic Fibrosis Foundation Therapeutics Incorporated; BioAxone Biosciences, Inc.; and Janssen Pharmaceuticals, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Vertex Pharmaceuticals Incorporated

    Corporate Governance 
    Vertex Pharmaceuticals Incorporated’s ISS Governance QuickScore as of Feb 1, 2015 is 9. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 10; Compensation: 7.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Dr. Jeffrey M. Leiden M.D., Ph.D., 59
    Chairman, Chief Exec. Officer and Pres
    Mr. Ian F. Smith CPA, ACA, 49
    Chief Financial Officer and Exec. VP
    Dr. David Altshuler M.D., Ph.D., 50
    Chief Scientific Officer and Exec. VP of Global Research
    Mr. Stuart A. Arbuckle , 49
    Chief Commercial Officer and Exec. VP
    Mr. Kenneth L. Horton , 48
    Special Counsel to the Chief Exec. Officer
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders